MEDICAL WEIGHT LOSS · KATY, TX
Medical Weight Loss in Katy, TX
Clinically Proven. Physician-Supervised.
Stubborn weight that won't respond to diet and exercise alone isn't a willpower problem — it's a metabolic one. At Le Chloé MedSpa in Katy, TX, we offer physician-supervised medical weight loss programs using the most clinically advanced GLP-1 medications available, including semaglutide, tirzepatide, and retatrutide — each individually prescribed and monitored for your specific goals, health history, and body.
HOW IT WORKS
The science behind GLP-1 weight loss
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a natural hormone your body produces after eating — signaling the brain to reduce hunger, slowing the rate at which food leaves the stomach, and regulating blood sugar levels. The result is a significant reduction in appetite and caloric intake that leads to meaningful, sustained weight loss.
Unlike stimulant-based weight loss medications, GLP-1 medications work with your body's existing hormonal systems rather than forcing it into an artificial state. This is why clinical trials show unprecedented results — and why these medications have transformed the medical weight loss landscape entirely.
"Medical weight loss in Katy, TX has never been more effective. Today's GLP-1 medications deliver clinical results that were unimaginable just five years ago."
Your weight loss program
-
Free consultation with a physician-supervised provider
-
Full health assessment and medical history review
-
Personalized medication selection and starting dose
-
Gradual dose escalation for maximum tolerance
-
Weekly self-administered subcutaneous injection at home
-
Ongoing provider monitoring and dose adjustments
-
Nutritional guidance and lifestyle support throughout
-
Regular progress check-ins and goal reassessment
OUR WEIGHT LOSS PROGRAMS
Semaglutide, Tirzepatide & Retatutide in Katy, TX
We offer three generations of GLP-1 weight loss medication — each progressively more powerful. Your provider will recommend the right medication based on your health history, weight loss goals, tolerance, and budget at your free consultation.
GLP-1 AGONIST
Semaglutide
~10–15% body weight loss
FROM $299/MONTH
The proven gold standard of GLP-1 weight loss
Semaglutide is an FDA-approved GLP-1 receptor agonist — the active ingredient in Ozempic® and Wegovy® — that works by mimicking the GLP-1 hormone to regulate appetite, slow gastric emptying, and reduce hunger signals. Clinical studies show an average weight loss of 10–15% of body weight over 12–16 months.
Administered as a once-weekly subcutaneous injection at home, semaglutide is the foundation of Le Chloé MedSpa's physician-supervised medical weight loss program in Katy, TX — and the most widely studied GLP-1 medication available.
AVERAGE LOSS
10–15%
FREQUENCY
Weekly
STARTING FROM
$299/mo
DUAL GIP/GLP-1 AGONIST
Tirzepatide
~15–22% body weight loss
MOST POPULAR PROGRAM
Two hunger hormones. Greater results
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the active ingredient in Mounjaro® and Zepbound® — that simultaneously activates two hunger-regulating hormones for a more powerful metabolic effect than semaglutide alone. Clinical trials have shown average weight loss of 15–22% of body weight, making it one of the most effective weight loss medications currently available.
Like semaglutide, it is administered as a once-weekly injection and is offered through Le Chloé MedSpa's physician-supervised weight loss program with full provider monitoring and dose management throughout.
AVERAGE LOSS
15–22%
FREQUENCY
Weekly
RECEPTORS
Dual
TRIPLE AGONIST · NEW GEN
Retatrutide
~24–28% body weight loss
COMPOUNDED PROTOCOL
The next generation of metabolic medicine
Retatrutide is the first triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — representing the next evolution in incretin-based metabolic therapy. While semaglutide targets one receptor and tirzepatide targets two, retatrutide activates all three metabolic hormone pathways in a single molecule for the most comprehensive weight loss effect of any medication in clinical development.
Phase 2 trials showed up to 24.2% body weight loss at 48 weeks, with newer 68-week data showing 28.7% loss at the highest dose — outperforming both semaglutide and tirzepatide. Currently available as a physician-supervised compounded protocol while Phase 3 trials are completed.
Important note: Retatrutide is not yet FDA-approved for weight management and is available as a compounded protocol under physician supervision. All patients are fully informed of its clinical status before beginning treatment.
SIDE BY SIDE
Comparing our weight loss programs
SEMAGLUTIDE
TIRZEPATIDE
RETATRUTIDE
24–28%
GLP-1 + GIP + Glucagon
Phase 3 (compounded)
Weekly injection
Consultation required
Average weight loss
Hormone receptor targeted
FDA approval status
Administration
Starting price at Le Chloé
10–15%
GLP-1
FDA-approved
Weekly injection
From $299/mo
15–22%
GLP-1 + GIP
FDA-approved
Weekly injection
Consultation required
Frequently asked questions
Designed by Aurora
Start your physician-supervised weight loss program at Le Chloé MedSpa in Katy, TX
READY TO BEGIN?
RELATED TREATMENTS
Explore more at Le Chloé
WELLNESS
Peptide Therapy
WELLNESS
Vitamin Injections
WELLNESS
IV Therapy